Despite HCR's theoretical advantages as outlined above, it is a novel innovative approach that has not been studied in a randomized setting, nor in the context of diabetic patients. Its rationale and main research question stem from MICS CABG work by the principal investigator, as well as his recent, collaborative Lancet meta-analysis which revealed that diabetic patients with multivessel coronary disease (CAD) have better much survival with bypass surgery than with stents8. However, diabetics are also the patients who experience the most complications and infections from cCABG with incision of the breastbone. The investigators main hypothesis is therefore that a HCR strategy in diabetics with multivessel CAD will combine the benefits of bypass surgery on the artery at the front of the heart (the LAD), nearly eliminate the risk of complications and wound infection, and allow for faster recovery and improved quality of life when compared to cCABG. Other blockages would be treated with a PCI/DES to reduce the invasiveness of the procedure.